Project/Area Number |
15K09158
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Cardiovascular medicine
|
Research Institution | Okayama University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
赤木 達 岡山大学, 医歯薬学総合研究科, 助教 (60601127)
阪口 政清 岡山大学, 医歯薬学総合研究科, 准教授 (70379840)
伊藤 浩 岡山大学, 医歯薬学総合研究科, 教授 (90446047)
|
Project Period (FY) |
2015-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2015: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Keywords | 肺高血圧症 / ナノメディシン / 終末糖化産物受容体 / 肺動脈平滑筋細胞 / drug delivery system / 細胞増殖 / 右室収縮期圧 / 右室肥大 / 肺高血圧 / 血小板由来増殖因子 / S100蛋白 / TIRAP / 炎症 |
Outline of Final Research Achievements |
1.After a single administration, imatinib or beraprost-nanoparticles significantly decreased right ventricular pressure and right ventricular hypertrophy in rat models of pulmonary arterial hypertension (PAH). 2.Pulmonary artery smooth muscle cells of PAH (PAH-PASMCs) were hyperplastic. AS-1, an inhibitor of TIR domain-mediated RAGE signaling, significantly inhibited overgrowth in PAH-PASMCs.
|